08:00 , Mar 3, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interferon induced with helicase C domain 1 (IFIH1; MDA5)

Cancer INDICATION: Prostate cancer Cell culture and mouse studies suggest IFIH1 could help treat prostate cancer. In a mouse prostate cancer cell line, viral vector-mediated overexpression of mouse IFIH1 decreased proliferation and increased pro-apoptotic signaling compared with...
07:00 , May 18, 2015 |  BioCentury  |  Emerging Company Profile

RIG-ged against cancer

Rigontec GmbH is incorporating lessons from over a decade of research on oligonucleotide therapeutics to develop cancer therapies targeting RIG-I, an immune-stimulating receptor related to toll-like receptors that may have more tumor-specific activity than TLRs. ...
07:00 , Aug 20, 2012 |  BC Week In Review  |  Clinical News

MultiCell Technologies preclinical data

In vitro, MCT-465 showed no cytotoxicity or anti-proliferative effect in several human HCC cell lines. The compound is a high molecular weight synthetic double-stranded RNA with immune enhancing properties mediated by toll-like receptor 3...
08:00 , Jan 5, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) DEAD box polypeptide 58 (DDX58; RIG-I); interferon induced with helicase C domain 1 (IFIH1;...
07:00 , Aug 27, 2009 |  BC Innovations  |  Targets & Mechanisms

Melanoma: eaten up inside

Autophagy's dual pro- and antiapoptotic roles make it hard to determine whether inducing the process could be a viable strategy to treat cancer. In melanoma, a team led by Spanish researchers thinks the answer is...
07:00 , Aug 13, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Interferon induced with...
07:00 , Jul 30, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Interferon induced with...
07:00 , Mar 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Endocrine disease ...